Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Citalopram for Vasomotor and Urogenital Syndromes in Post-menopause
NCT05346445Completed
- Sponsor
- Hospital Regional 1° de Octubre
- Start
- Jan 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of citalopram in vasomotor symptoms and genitourinary syndrome of menopause (GSM) (2 arms), sponsored by Hospital Regional 1° de Octubre. Primary endpoints: Change from baseline Menopause Rating Scale (MRS) total score at 3 months, Change from baseline Menopause Rating Scale (MRS) total score at 6 months and 4 more. Started Jan 2021; status: completed.
02
Drugs
citalopram
03
Conditions
vasomotor symptomsgenitourinary syndrome of menopause (GSM)
Beyond the preview
Go deeper on NCT05346445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346445.